FDA approves skin cancer vaccine by...?

根据「FDA approves skin cancer vaccine by...?」的最新预测市场数据，交易者已形成强烈共识。

目前，December 31, 2027 以压倒性的 60.5% 获胜概率主导市场；June 30, 2027 以 28.5% 位居第二。该市场的下注量已达 $96.5K，反映出市场的高度关注。

为了更好地评估各潜在结果的位置，可依据隐含概率与合约定价将市场划分为三个明显的交易梯队：

🥇 第一梯队：绝对领跑者

• December 31, 2027 (60.5%)：December 31, 2027 目前拥有最高概率，深受订单簿青睐。看好该结果的交易者面对的「Buy Yes」合约价为 61¢，显示出市场的高度确信。仅该合约就已产生 $82.3K 的成交量。

🥈 第二梯队：主要挑战者

• June 30, 2027 (28.5%)：作为最可行的替代选项，June 30, 2027 保持着 28.5% 的成真概率，其「Buy Yes」份额目前成交价为 28¢。

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants approval of intismeran autogene for any indication by December 31, 2027, 11:59 PM ET. Otherwise, this market will resolve to "No".

Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.

Differences in neoantigen composition between patients will not affect resolution. Changes to the product's formulation will not affect resolution, provided the FDA approves the product described above. Approval as part of a combination regimen will qualify. Approval for a narrower population than the one studied in INTerpath-001 will qualify. Approval for an indication other than melanoma will also qualify. Both standard and accelerated approval will qualify.

An approval is defined as:

For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)

For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced

For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)

For biosimilars: FDA approval of a 351(k) application

The following constitute qualifying approvals:

Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

The following do not constitute qualifying approvals:

Approvable letters that require additional actions before approval

Tentative approvals pending patent or exclusivity expiration

FDA requests for additional information or studies

Extension of Prescription Drug User Fee Act (PDUFA) dates

Approval for compassionate use or expanded access programs only

Approval only for export or for use outside the United States

Emergency Use Authorization (EUA) without full approval

Complete Response Letters (CRLs) indicating the application cannot be approved in its current form

If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval.

Conditional approvals may include post-marketing requirements or commitments and still qualify.

The primary resolution source for this market will be official information from the FDA; however, a consensus of credible reporting may also be used.

人群共识与投机成交塑造了更宏观的预测市场，而我们的量化算法提供了数据驱动的反向视角。通过分析基本面信号、底层趋势与历史分布，我们的 AI 估值模型为每个结果独立测算出一个「公允价值」概率。

将该公允价值与当前交易价值对比，可揭示出重大背离——即期望值（EV）差。正 EV 差代表统计上被低估的结果，而负 EV 差则提示市场可能存在反应过度。

顶级 AI Alpha 与错误定价套利机会

根据最新一轮数据模型测算，以下几个关键合约存在显著偏离：

• 最被高估的结果：June 30, 2027 当前交易价为 28.5%，但我们的 AI 测算其公允价值仅为 17.8%，形成 -10.7% 的较大负 EV 差，表明人群可能过度炒作该结果、把溢价推得过高。
• 最佳价值标的（最高 EV）：我们的模型将 December 31, 2027 识别为盘面上最具价值的机会。市场仅给予其 60.5% 的交易概率，而我们 AI 的公允价值评估为 67%——形成可观的 +6.5% EV 差。